“As some are now calling it, the greater Philadelphia region, or ‘Cellicon Valley’ is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US. The nickname comes from the city’s storied history in the field, eventually achieving the first FDA-approved gene and cell therapies, and its current position as a global leader in advancing gene and cell therapy research, out of which a whole commercial biotech ecosystem is flourishing. We caught up with Lisa Dalton, Chief People Officer, Spark Therapeutics,to dive into why Philly’s talent market is a key asset that can propel the city to be a top biotech cluster.”